Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Type of study
Language
Document Type
Year range
1.
Mult Scler Relat Disord ; 49: 102777, 2021 Apr.
Article in English | MEDLINE | ID: covidwho-1036334

ABSTRACT

We report the case of a MS patient on subcutaneous ofatumumab who became infected with SARS-CoV-2 and remained asymptomatic while developing antiviral IgM and IgG antibodies. The patient was B-cell depleted with normal serum immunoglobulin levels. Anti-SARS-CoV-2 IgG antibodies remained positive three months after the initial infection. These findings suggest that a MS patient treated with ofatumumab may be able to mount an effective humoral response to SARS-CoV-2 infection and probably to COVID-19 vaccines as well. Further research will be necessary to evaluate the humoral response of MS patients on ofatumumab to SARS-CoV-2 infection and COVID-19 vaccines.


Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Antibodies, Viral/blood , COVID-19/immunology , Multiple Sclerosis , Humans , Immunity, Humoral , Immunoglobulin G/blood , Immunoglobulin M/blood , Multiple Sclerosis/drug therapy , Multiple Sclerosis/immunology , Multiple Sclerosis/virology , SARS-CoV-2
SELECTION OF CITATIONS
SEARCH DETAIL